NSRX Stock Summary and Trading Ideas (Nasus Pharma Ltd. | AMEX:NSRX)

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Nasus Pharma Ltd. trades on the AMEX stock market under the symbol NSRX.

As of September 9, 2026, NSRX stock price declined to $3.55 with 4,439 million shares trading.

NSRX has a beta of 1.45, meaning it tends to be more sensitive to market movements. NSRX has a correlation of 0.03 to the broad based SPY ETF.

NSRX has a market cap of $41.57 million. This is considered a Sub-Micro Cap stock.

NSRX has underperformed the market in the last year with a price return of -55.6% while the SPY ETF gained +18.4%. However, in the short term, NSRX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +22.4% vs +3.7% return in SPY. But in the last 2 weeks, NSRX shares have been beat by the market, returning -12.3% compared to an SPY return of -0.5%.

NSRX support price is $3.55 and resistance is $4.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NSRX shares will trade within this expected range on the day.